Physician profile
David S Rosenberg
NPI 1770618548
$10,710.78
in general payments reported to CMS, 2019-2025
14 companies · $901 in 2025
The $901 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,735 · 2020: $269 · 2021: $641 · 2022: $807 · 2023: $1,372 · 2024: $3,985 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,139 · Consulting Fee: $75.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,138.72 |
| Consulting Fee | $75.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $3,270.31 | 2024-2025 | Daxxify, Daxi |
| Kci USA, INC. | $2,513.27 | 2019-2020 | |
| Abbvie INC. | $2,132.26 | 2023-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Allergan, INC. | $914.43 | 2019-2022 | |
| Merz North America, INC. | $697.32 | 2019-2025 | Xeomin |
| Sientra, INC. | $442.96 | 2019-2021 | |
| Galderma Laboratories, L.P. | $299.14 | 2021-2025 | Dysport |
| Becton, Dickinson and Company | $200.00 | 2022 | |
| Smith+Nephew, INC. | $83.44 | 2023-2025 | Pico |
| Medtronic, INC. | $75.00 | 2023 | Surgipro Ll, Merocel |
| Axogen | $27.44 | 2019 | |
| Kerecis Limited | $20.90 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Endo Pharmaceuticals INC. | $17.87 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $16.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.